Blenrep

Active Ingredient(s): Belantamab Mafodotin-blmf
FDA Approved: * August 5, 2020
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Blenrep Overview

Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.[1][2][3][4] The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.[1][2] Belantamab mafodotin is a humanized IgG1κ monocl...

Read more Blenrep Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Belantamab_mafodotin

Recent Blenrep Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Blenrep: (1 result)

Sorted by National Drug Code

• 0173-0896 Blenrep 50 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Glaxosmithkline LLC

Other drugs which contain Belantamab Mafodotin-blmf or a similar ingredient: (1 result)

• BELANTAMAB MAFODOTIN